Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

More articles from ENDOCRINE AND DIABETES

  • You have access
    LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice
    David R. Powell, Melinda G. Smith, Deon D. Doree, Angela L. Harris, Jennifer Greer, Christopher M. DaCosta, Andrea Thompson, Sabrina Jeter-Jones, Wendy Xiong, Kenneth G. Carson, Nicole C. Goodwin, Bryce A. Harrison, David B. Rawlins, Eric D. Strobel, Suma Gopinathan, Alan Wilson, Faika Mseeh, Brian Zambrowicz and Zhi-Ming Ding
    Journal of Pharmacology and Experimental Therapeutics July 2017, 362 (1) 85-97; DOI: https://doi.org/10.1124/jpet.117.240820
  • You have access
    The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes
    Sara T. Hjuler, Sofie Gydesen, Kim V. Andreassen, Morten A. Karsdal and Kim Henriksen
    Journal of Pharmacology and Experimental Therapeutics July 2017, 362 (1) 24-30; DOI: https://doi.org/10.1124/jpet.117.241281
  • You have access
    Endothelin Confers Protection against High Glucose-Induced Neurotoxicity via Alleviation of Oxidative Stress
    Mohamed A. Fouda and Abdel A. Abdel-Rahman
    Journal of Pharmacology and Experimental Therapeutics April 2017, 361 (1) 130-139; DOI: https://doi.org/10.1124/jpet.116.238659
  • You have access
    Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
    Elisa Benetti, Raffaella Mastrocola, Giovanna Vitarelli, Juan Carlos Cutrin, Debora Nigro, Fausto Chiazza, Eric Mayoux, Massimo Collino and Roberto Fantozzi
    Journal of Pharmacology and Experimental Therapeutics October 2016, 359 (1) 45-53; DOI: https://doi.org/10.1124/jpet.116.235069
  • Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features
    You have access
    Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features
    Ryuichi Ohgaki, Ling Wei, Kazunori Yamada, Taiki Hara, Chiaki Kuriyama, Suguru Okuda, Kiichiro Ueta, Masaharu Shiotani, Shushi Nagamori and Yoshikatsu Kanai
    Journal of Pharmacology and Experimental Therapeutics July 2016, 358 (1) 94-102; DOI: https://doi.org/10.1124/jpet.116.232025
  • You have access
    In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog
    Rebecca A. Owens, Ryan J. Hansen, Steven D. Kahl, Chen Zhang, Xiaoping Ruan, Anja Koester, Shun Li, Hui-Rong Qian, Mark W. Farmen, M. Dodson Michael, Julie S. Moyers, Gordon B. Cutler, Andrew Vick and John M. Beals
    Journal of Pharmacology and Experimental Therapeutics June 2016, 357 (3) 459-465; DOI: https://doi.org/10.1124/jpet.115.231035
  • You have access
    Inhibition of the Inflammasome NLRP3 by Arglabin Attenuates Inflammation, Protects Pancreatic β-Cells from Apoptosis, and Prevents Type 2 Diabetes Mellitus Development in ApoE2Ki Mice on a Chronic High-Fat Diet
    Amna Abderrazak, Khadija El Hadri, Elodie Bosc, Bertrand Blondeau, Mohamed-Naceur Slimane, Berthold Büchele, Thomas Simmet, Dominique Couchie and Mustapha Rouis
    Journal of Pharmacology and Experimental Therapeutics June 2016, 357 (3) 487-494; DOI: https://doi.org/10.1124/jpet.116.232934
  • You have access
    Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas
    Ryo Ito, Yoshiyuki Tsujihata, Masami Suzuki, Kazumasa Miyawaki, Kae Matsuda and Koji Takeuchi
    Journal of Pharmacology and Experimental Therapeutics April 2016, 357 (1) 217-227; DOI: https://doi.org/10.1124/jpet.115.230730
  • Peripheral Adenosine A<sub>3</sub> Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H<sub>1</sub> Receptors
    You have access
    Peripheral Adenosine A3 Receptor Activation Causes Regulated Hypothermia in Mice That Is Dependent on Central Histamine H1 Receptors
    Jesse Lea Carlin, Dilip K. Tosh, Cuiying Xiao, Ramón A. Piñol, Zhoumou Chen, Daniela Salvemini, Oksana Gavrilova, Kenneth A. Jacobson and Marc L. Reitman
    Journal of Pharmacology and Experimental Therapeutics February 2016, 356 (2) 474-482; DOI: https://doi.org/10.1124/jpet.115.229872
  • You have access
    A Novel Allosteric Insulin Receptor–Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys
    Padma Bezwada, Jingsong Zhao, Ken Der, Bob Shimizu, Liching Cao, Ago Ahene, Paul Rubin and Kirk Johnson
    Journal of Pharmacology and Experimental Therapeutics February 2016, 356 (2) 466-473; DOI: https://doi.org/10.1124/jpet.115.229690

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 17
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics